Statement of Facts in DPA are Binding on Defendant and Can Establ
In Humana Inc. v. Actavis Elizabeth LLC, et al. (EDPA July 27, 2026), a judge held that facts admitted in a DOJ Deferred Prosecution Agreement are binding in follow-on civil antitrust cases. The ruling relied on Teva’s Rule 36 admissions quoting its DPA Statement of Facts, granting partial summary judgment on a Section 1 per se price-fixing claim.
How this was made
The 30-second read
Why it matters
It highlights that Rule 36 admissions tied to DPA facts can have conclusive effect for summary judgment, and that late challenges to RFAs may be waived. This increases litigation certainty for plaintiffs and can shift negotiation dynamics for defendants with DPAs or NPAs.
Market read
The article is a legal precedent that can increase perceived civil antitrust liability risk for DPA/NPA counterparties, but it does not provide new Teva financial metrics or a new settlement/damages figure.
What to watch
Traders may be over-weighting precedent versus the current procedural posture (e.g., remaining claims, damages phase timing, and whether Teva can still narrow scope through other defenses not addressed by the RFA waiver).
Background
The piece discusses an Eastern District of Pennsylvania opinion in Humana Inc. v. Actavis Elizabeth LLC within the In re Generic Pharmaceuticals Pricing Antitrust Litigation, focusing on how DOJ DPA Statement of Facts admissions can bind defendants in subsequent civil cases.
Ticker impact
The article centers on Teva’s DPA Statement of Facts being treated as binding admissions in the Generics MDL, enabling plaintiffs’ partial summary judgment.
Near-term repricing risk for Teva on any incremental civil-case developments tied to the ruling, though the article itself is legal analysis rather than a new filing.
The text describes a July 27, 2026 opinion with direct procedural consequences for how DPA facts are used in civil cases, but it does not report a new Teva-specific financial disclosure or fresh damages/settlement amount.
Market effects
Sets a precedent for generic-drug antitrust cases, potentially raising perceived civil exposure for other DOJ DPA/NPA counterparties.
Primarily US litigation impact, with potential spillover to US-listed generic manufacturers.
Could affect global generic pricing-antitrust risk assessments for multinational pharma groups with US enforcement exposure.
Counterpoint
Because the article is a legal precedent discussion, it may not change Teva’s immediate cash flows unless it triggers new rulings, damages updates, or settlement talks.
Key entities
- companyTeva Pharmaceuticals
Defendant in a parallel DOJ antitrust investigation and DPA whose Statement of Facts admissions were used via Rule 36 in the MDL.
- governmentDepartment of Justice (DOJ) Antitrust Division
Entered into a DPA with Teva and provided the Statement of Facts that later became binding in civil litigation.
- courtEastern District of Pennsylvania
Issued the July 27, 2026 opinion on the binding effect of DPA Statement of Facts admissions in civil antitrust cases.
